AOD-9604

AOD-9604 is a 16-amino acid synthetic peptide corresponding to residues 177-191 of human growth hormone (hGH), with a tyrosine residue appended at the N-terminus to stabilize the structure. It was designed to isolate the lipolytic activity attributed to the C-terminal tail of hGH while discarding the growth-promoting and diabetogenic properties of the intact hormone.

Unlike full-length hGH, AOD-9604 does not bind the classical growth hormone receptor and does not stimulate production of insulin-like growth factor-1 (IGF-1). It also does not induce cell proliferation. These distinctions mean the peptide carries none of the hyperglycemic, anti-insulin, or tissue-growth effects associated with exogenous hGH administration.

The primary mechanism of lipolytic action appears to involve upregulation of the beta-3 adrenergic receptor (β3-AR) in adipose tissue. Animal experiments by Heffernan and colleagues (Endocrinology, 2001) demonstrated that chronic AOD-9604 treatment restored suppressed β3-AR mRNA levels in obese mice to those observed in lean controls. Critically, when the same compound was tested in β3-AR knockout mice, chronic weight-reduction and lipolytic effects were largely abolished, implicating the receptor as essential for the sustained metabolic response.

• Stimulates lipolysis (fat breakdown) in adipose tissue • Inhibits lipogenesis (fat synthesis) • Upregulates β3-AR expression in adipocytes • No GH receptor binding; no IGF-1 elevation • No impairment of glucose tolerance or insulin sensitivity at tested doses

The foundational animal data were generated at Monash University by Professor Frank Ng and colleagues in the late 1990s and early 2000s. In Zucker fatty rats, oral AOD-9604 at 500 mcg/kg/day for 19 days reduced body weight gain by more than 50% compared with controls and increased lipolytic activity in adipose tissue, without adverse effects on insulin sensitivity as assessed by euglycemic clamp (Ng FM et al., Horm Res 2000; PMID 11146367). Separate studies in obese ob/ob mice confirmed increased in vivo fat oxidation and elevated plasma glycerol — a marker of lipolysis — without hyperglycemia or suppression of insulin secretion (Heffernan MA et al., Int J Obes Relat Metab Disord 2001; PMID 11673763).

Six human Phase I and Phase II trials enrolling approximately 900 participants in total were conducted by Metabolic Pharmaceuticals Limited. A 12-week Phase IIa randomized oral trial in approximately 300 obese participants across five sites compared doses of 1, 5, 10, 20, and 30 mg/day against placebo. The 1 mg/day group lost a mean of 2.8 kg versus 0.8 kg for placebo over 12 weeks; notably, higher doses did not produce proportionally greater weight loss, suggesting a non-linear dose-response. No serious adverse events attributable to the compound were reported, and no clinically meaningful changes in IGF-1, fasting glucose, or insulin were detected.

A larger 24-week Phase IIb randomized, double-blind, placebo-controlled multicenter trial in 536 subjects subsequently failed to demonstrate statistically significant weight loss compared with placebo at the primary endpoint. Metabolic Pharmaceuticals discontinued obesity development in 2007 on this basis.

In a separate line of research, Kwon and Park (Ann Clin Lab Sci 2015; PMID 26275694) tested intra-articular AOD-9604 in a collagenase-induced rabbit osteoarthritis model (n=32 animals, 4 groups). Combined AOD-9604 (0.25 mg) plus hyaluronic acid injections produced significantly lower cartilage degeneration scores and shorter lameness duration than either agent alone.

A forensic pharmacology study (Cox HD et al., Drug Test Anal 2015; PMID 25208511) identified six metabolites of AOD-9604 in serum and urine, confirming the peptide is detectable in biological samples. The World Anti-Doping Agency (WADA) prohibits the compound in sport.

In summary, animal evidence is consistent and mechanistically coherent, but the pivotal human obesity trial failed its primary endpoint. Evidence for fat loss in humans is not conclusive.

Typical dosage: 300 mcg (daily).

In the human Phase IIa clinical trial, oral doses ranging from 1 to 30 mg/day were evaluated over 12 weeks. The 1 mg/day oral dose produced the greatest observed weight reduction (approximately 2.8 kg mean loss). Higher oral doses did not show proportionally greater effect, and the compound was not advanced to an oral therapeutic product.

In current compounding and "research peptide" contexts, AOD-9604 is most often administered by subcutaneous injection rather than orally, on the rationale that peptide bioavailability via the oral route is likely inferior to the parenteral route (though this specific comparison has not been formally studied for AOD-9604). Community and clinical compounding protocols most frequently cite:

• 300 mcg per day subcutaneously, administered once daily in the morning in a fasted state • Some protocols extend the daily dose to 500 mcg/day, though no human data exist for this range via injection • Injections are typically placed in the periumbilical abdominal subcutaneous tissue using an insulin-gauge syringe (29-31 G) • Cycle lengths commonly described range from 8 to 12 weeks, with a break thereafter • Administration in the fasted state is suggested by practitioners on the basis that endogenous lipolysis is already elevated during fasting, but this rationale has not been tested in a controlled human trial for AOD-9604 specifically

No FDA-approved dosing exists for AOD-9604. The 300-500 mcg/day subcutaneous figures derive from clinical compounding practice and community reporting, not from peer-reviewed human pharmacokinetic or dose-finding studies.

This information is provided for educational and reference purposes only and does not constitute medical advice. AOD-9604 is not approved by the FDA for any therapeutic indication, and use outside of licensed clinical investigation carries unknown risks.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In the intra-articular osteoarthritis setting, the only combination with an actual controlled animal study is AOD-9604 plus hyaluronic acid (HA). The Kwon and Park (2015) rabbit model found that combined injection produced superior cartilage preservation and faster functional recovery than either agent alone, suggesting potentially complementary mechanisms (AOD-9604 for cartilage matrix effects, HA for joint lubrication and cushioning).

All of the following combinations are anecdotal, drawn from community and clinical compounding practice with no randomized human trial support:

• AOD-9604 plus CJC-1295 (a GHRH analogue): frequently reported together under the rationale that CJC-1295 stimulates pulsatile GH release while AOD-9604 provides direct lipolytic signaling, potentially offering complementary fat-loss mechanisms without full GH receptor agonism.

• AOD-9604 plus Ipamorelin (a GHRP): similar rationale; Ipamorelin stimulates GH secretion from the pituitary with a relatively selective side-effect profile, while AOD-9604 is intended to act peripherally on adipose tissue.

• Triple combination of AOD-9604, CJC-1295, and Ipamorelin is marketed by multiple compounding pharmacies as a body-composition blend. No clinical trial data exist for this combination.

The mechanistic logic behind these combinations is plausible but entirely speculative in the absence of human efficacy data. Interaction safety data are unavailable.

AOD-9604 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Minimal side effects reported

The human clinical trial program, which enrolled approximately 900 participants across six studies with the longest duration of 24 weeks, reported a favorable safety profile. No serious adverse events were attributed to AOD-9604 in any trial. There were no treatment-related discontinuations, no clinically meaningful elevations in IGF-1, no changes in fasting glucose or insulin sensitivity, and no detectable anti-AOD-9604 antibodies formed in any participant. This absence of IGF-1 stimulation and glucose disruption is considered an important advantage over full-length exogenous hGH.

Mild adverse effects reported at similar or slightly higher frequency than placebo in oral trials included: headache, nausea (more common at doses above 1 mg orally), and upper respiratory symptoms. No cardiovascular, hepatic, or renal signals emerged in the trial program.

With the subcutaneous injection route used in current compounding practice, injection-site reactions (transient redness, mild swelling, tenderness) are the most commonly reported local effects, consistent with other peptide injectables.

Important caveats and contraindications:

• Long-term safety (beyond 24 weeks) has not been studied in humans. • AOD-9604 is listed by the FDA as a bulk drug substance that may present significant safety risks for compounding, meaning it has not been cleared for use in outsourcing pharmacy or 503B compounding. • The compound is prohibited by WADA and may constitute an anti-doping violation in competitive sport. • No safety data exist for use during pregnancy, lactation, pediatric populations, or in individuals with active malignancy. Given structural similarity to a domain of hGH, use in these populations is inadvisable. • Because the compound is sold as a "research chemical" without pharmaceutical-grade regulation in many markets, product purity and sterility cannot be guaranteed, which represents an independent risk.